Fibrosarcoma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032
Fibrosarcomas are malignant neoplasms of fibroblasts with varying collagen production and a "herringbone" architecture. Fibrosarcomas typically originate from the fascia and soft tissue tendons but can also occur in bones as primary or secondary tumors in the medullary canal or periosteum. These tumors derive from a mesenchymal cell origin, composed of spindle-cell fibroblasts with uncontrolled proliferation. Fibrosarcomas are divided into infantile (rarely metastasizing) and adult-type (highly malignant). Previous bone damage or radiotherapy may increase the risk of fibrosarcoma of the bone. Surgical excision is the primary treatment for localized soft tissue sarcomas. Some diagnoses include low-grade fibromyxoid sarcomas, sclerosing epithelioid fibrosarcomas, fibrosarcomatous dermatofibrosarcoma protuberans, and synovial sarcomas, which may be mistaken for adult fibrosarcoma. Most adult fibrosarcomas (80%) are high-grade, with a survival rate of less than 70% at two years and less than 55% at five years, despite some low-grade lesions progressing to high-grade sarcoma with many local recurrences and lymph and parenchymal metastases.
·
Fibrosarcomas represent only about 10% of
musculoskeletal sarcomas and fewer than 5% of all primary tumor of bone.
Thelansis’s “Fibrosarcoma Market
Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022
To 2032" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Fibrosarcoma treatment modalities options
for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and
China).
KOLs insights
of Fibrosarcoma across 8 MM market from the centre of Excellence/ Public/
Private hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Fibrosarcoma Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment